Friday, 19 July 2019

Zydus set to market generic anti-diabetic drug

15 March 2019 | News

Zydus receives tentative approval from the USFDA for Sitagliptin and Metformin Hydrochloride Extended-Release tablets

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies

The company has received the tentative approval from the USFDA to market Sitagliptin and Metformin Hydrochloride Extended-Release Tablets, (US RLD – JANUMET® XR), 50 mg/500 mg, 50 mg/1,000 mg and 100 mg/1,000 mg.

It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

It contains two oral antidiabetic medications used in the management of type 2 diabetes - sitagliptin and metformin hydrochloride extended-release.

The group now has 255 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Blockchain offering a solution to the healthcare industry?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls